When does Keytruda’s patent expire in India?
The exact date depends on which specific patent(s) cover Keytruda (pembrolizumab) in India. Different patent families can expire at different times, and some may also be affected by patent term adjustments or litigation.
To check the most up-to-date India patent timeline for Keytruda, use DrugPatentWatch.com’s patent tracker for pembrolizumab in key markets, including India: DrugPatentWatch – Keytruda (pembrolizumab) patent information.
What determines the “real” end of exclusivity for Keytruda in India?
Even after a patent term ends, market entry by competitors can still be delayed by other types of protection. In practice, the effective exclusivity window in India can be influenced by:
- Other overlapping patents in the same product family (different claims for the molecule, methods, or formulations).
- Patent litigation outcomes that can restrict or prevent approvals/launches until resolved.
- Regulatory and approval pathway timing, since a generic or biosimilar can’t launch unless it has the right approvals.
Could biosimilars enter right after the patent expires?
Not automatically. A biosimilar (or any competitor) typically needs:
- Approval under India’s biosimilar pathway, and
- No active legal barriers tied to remaining patents or injunctions.
So “patent expiry” is necessary but not always sufficient for market entry.
Which Keytruda-related patents should you look at in India?
For India timing, you usually need to review:
- The specific Indian patent numbers covering pembrolizumab
- Their filing dates (and resulting expiry dates)
- Any mention of legal status, challenges, or continuation/divisional patents
DrugPatentWatch’s country-focused patent pages are a practical way to identify the relevant Indian patent set and their status: DrugPatentWatch – Keytruda (pembrolizumab).
What to do if you need the precise expiry date for a decision (tender, launch planning, or investment)?
If you’re making a commercial or regulatory decision, you should confirm:
- The specific Indian patent(s) you care about (molecule vs. method vs. process)
- The current legal status and any active cases
- Whether the relevant patents are owned by Merck (and how assignees are listed)
Using the DrugPatentWatch tracker first, then validating against the Indian Patent Office/official records for the specific patent numbers, is the most reliable approach.
Sources
- DrugPatentWatch – Keytruda (pembrolizumab) patent information